Loading...
CDK9 inhibitors in acute myeloid leukemia
Boffo, S Damato, A Alfano, L Giordano, A
Boffo, S
Damato, A
Alfano, L
Giordano, A
Citations
Altmetric:
Genre
Review
Journal
Journal
Date
2018-02-23
Advisor
Committee member
Group
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.1186/s13046-018-0704-8
Abstract
© 2018 The Author(s). Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
Description
Citation
Citation to related work
Springer Science and Business Media LLC
Has part
Journal of Experimental and Clinical Cancer Research
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu